Johnson & Johnson Price to Sales Ratio 2010-2024 | JNJ
Historical PS ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current P/S ratio for Johnson & Johnson as of November 20, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-11-19 |
153.00 |
|
4.29 |
| 2024-09-30 |
162.06 |
$35.68 |
4.54 |
| 2024-06-30 |
145.06 |
$34.80 |
4.17 |
| 2024-03-31 |
155.72 |
$33.72 |
4.62 |
| 2023-12-31 |
153.13 |
$32.94 |
4.65 |
| 2023-09-30 |
150.96 |
$29.30 |
5.15 |
| 2023-06-30 |
159.29 |
$28.44 |
5.60 |
| 2023-03-31 |
148.04 |
$29.25 |
5.06 |
| 2022-12-31 |
167.54 |
$30.01 |
5.58 |
| 2022-09-30 |
153.95 |
$28.96 |
5.32 |
| 2022-06-30 |
166.16 |
$30.17 |
5.51 |
| 2022-03-31 |
164.86 |
$29.89 |
5.52 |
| 2021-12-31 |
158.11 |
$29.46 |
5.37 |
| 2021-09-30 |
148.28 |
$34.22 |
4.33 |
| 2021-06-30 |
150.36 |
$33.39 |
4.50 |
| 2021-03-31 |
149.07 |
$31.54 |
4.73 |
| 2020-12-31 |
141.87 |
$30.94 |
4.59 |
| 2020-09-30 |
133.27 |
$30.25 |
4.41 |
| 2020-06-30 |
125.05 |
$30.12 |
4.15 |
| 2020-03-31 |
115.80 |
$30.88 |
3.75 |
| 2019-12-31 |
127.98 |
$30.55 |
4.19 |
| 2019-09-30 |
112.73 |
$30.30 |
3.72 |
| 2019-06-30 |
121.36 |
$29.99 |
4.05 |
| 2019-03-31 |
120.97 |
$30.01 |
4.03 |
| 2018-12-31 |
110.95 |
$29.91 |
3.71 |
| 2018-09-30 |
118.03 |
$29.79 |
3.96 |
| 2018-06-30 |
102.97 |
$29.51 |
3.49 |
| 2018-03-31 |
107.95 |
$28.73 |
3.76 |
| 2017-12-31 |
116.95 |
$27.86 |
4.20 |
| 2017-09-30 |
108.17 |
$26.99 |
4.01 |
| 2017-06-30 |
109.37 |
$26.21 |
4.17 |
| 2017-03-31 |
102.29 |
$25.95 |
3.94 |
| 2016-12-31 |
94.01 |
$25.74 |
3.65 |
| 2016-09-30 |
95.73 |
$25.58 |
3.74 |
| 2016-06-30 |
97.65 |
$25.27 |
3.86 |
| 2016-03-31 |
86.49 |
$24.98 |
3.46 |
| 2015-12-31 |
81.52 |
$24.90 |
3.27 |
| 2015-09-30 |
73.54 |
$24.94 |
2.95 |
| 2015-06-30 |
76.18 |
$25.29 |
3.01 |
| 2015-03-31 |
78.07 |
$25.75 |
3.03 |
| 2014-12-31 |
80.59 |
$25.91 |
3.11 |
| 2014-09-30 |
81.61 |
$25.91 |
3.15 |
| 2014-06-30 |
79.56 |
$25.56 |
3.11 |
| 2014-03-31 |
74.19 |
$24.96 |
2.97 |
| 2013-12-31 |
68.68 |
$24.78 |
2.77 |
| 2013-09-30 |
64.56 |
$24.65 |
2.62 |
| 2013-06-30 |
63.47 |
$24.60 |
2.58 |
| 2013-03-31 |
59.81 |
$24.30 |
2.46 |
| 2012-12-31 |
51.02 |
$24.00 |
2.13 |
| 2012-09-30 |
49.72 |
$23.61 |
2.11 |
| 2012-06-30 |
48.31 |
$23.32 |
2.07 |
| 2012-03-31 |
46.71 |
$23.40 |
2.00 |
| 2011-12-31 |
46.04 |
$23.42 |
1.97 |
| 2011-09-30 |
44.30 |
$23.17 |
1.91 |
| 2011-06-30 |
45.86 |
$22.79 |
2.01 |
| 2011-03-31 |
40.49 |
$22.30 |
1.82 |
| 2010-12-31 |
41.89 |
$22.06 |
1.90 |
| 2010-09-30 |
41.61 |
$22.38 |
1.86 |
| 2010-06-30 |
39.29 |
$22.40 |
1.75 |
| 2010-03-31 |
42.98 |
$22.40 |
1.92 |
| 2009-12-31 |
42.14 |
$22.20 |
1.90 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
